217 related articles for article (PubMed ID: 20575982)
1. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia.
Favilla V; Cimino S; Castelli T; Madonia M; Barbagallo I; Morgia G
BJU Int; 2010 Dec; 106(11):1700-3. PubMed ID: 20575982
[TBL] [Abstract][Full Text] [Related]
2. Arteriosclerosis related factors had no clinical significant correlation with resistive index in symptomatic benign prostatic hyperplasia.
Takada S; Kurita Y; Imanishi T; Otsuka A; Shinbo H; Furuse H; Nakanishi T; Suzuki A; Takase H; Ozono S
Urology; 2011 Feb; 77(2):433-7. PubMed ID: 21168193
[TBL] [Abstract][Full Text] [Related]
3. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
[TBL] [Abstract][Full Text] [Related]
4. Ejaculatory dysfunction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Rosen RC; Fitzpatrick JM;
BJU Int; 2009 Oct; 104(7):974-83. PubMed ID: 19426189
[TBL] [Abstract][Full Text] [Related]
5. Association between erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia in Nigerian men.
Ikuerowo SO; Akindiji YO; Akinoso OA; Akinlusi FM; Esho JO
Urol Int; 2008; 80(3):296-9. PubMed ID: 18480635
[TBL] [Abstract][Full Text] [Related]
6. A 10-year follow-up after transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia; long-term results of a randomized controlled trial.
Hoekstra RJ; Van Melick HH; Kok ET; Ruud Bosch JL
BJU Int; 2010 Sep; 106(6):822-6. PubMed ID: 20184573
[TBL] [Abstract][Full Text] [Related]
7. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia.
Hong SK; Lee ST; Jeong SJ; Byun SS; Hong YK; Park DS; Hong JY; Son JH; Kim C; Jang SH; Lee SE
BJU Int; 2010 May; 105(10):1424-8. PubMed ID: 19874305
[TBL] [Abstract][Full Text] [Related]
8. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men.
Trifiro MD; Parsons JK; Palazzi-Churas K; Bergstrom J; Lakin C; Barrett-Connor E
BJU Int; 2010 Jun; 105(11):1554-9. PubMed ID: 20002438
[TBL] [Abstract][Full Text] [Related]
9. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
[TBL] [Abstract][Full Text] [Related]
10. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
[TBL] [Abstract][Full Text] [Related]
11. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Stief CG; Porst H; Neuser D; Beneke M; Ulbrich E
Eur Urol; 2008 Jun; 53(6):1236-44. PubMed ID: 18281145
[TBL] [Abstract][Full Text] [Related]
12. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Brisinda G; Cadeddu F; Vanella S; Mazzeo P; Marniga G; Maria G
Urology; 2009 Jan; 73(1):90-4. PubMed ID: 18995889
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia.
Tan MO; Karabiyik I; Uygur MC; Diker Y; Erol D
Int Urol Nephrol; 2003; 35(3):357-63. PubMed ID: 15160539
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article].
Caremel R; Oger-Roussel S; Behr-Roussel D; Grise P; Giuliano F
Prog Urol; 2010 Oct; 20(9):616-26. PubMed ID: 20951929
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study.
Donatucci CF; Brock GB; Goldfischer ER; Pommerville PJ; Elion-Mboussa A; Kissel JD; Viktrup L
BJU Int; 2011 Apr; 107(7):1110-6. PubMed ID: 21244606
[TBL] [Abstract][Full Text] [Related]
16. Ejaculatory dysfunction and its association with lower urinary tract symptoms of benign prostatic hyperplasia and BPH treatment.
Hellstrom WJ; Giuliano F; Rosen RC
Urology; 2009 Jul; 74(1):15-21. PubMed ID: 19428091
[TBL] [Abstract][Full Text] [Related]
17. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines.
Cornu JN; Cussenot O; Haab F; Lukacs B
Eur Urol; 2010 Sep; 58(3):450-6. PubMed ID: 20554374
[TBL] [Abstract][Full Text] [Related]
18. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
Barqawi AB; Myers JB; O'Donnell C; Crawford ED
BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
20. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
